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The isolation of the human form of PHI (peptide HI) is described. The peptide was purified from human 
colonic extracts by using a chemical method for the detection of its C-terminal amidated structure. Human 
PHI consists of 27 amino acid residues and the complete amino acid sequence is: His-Ala-Asp-Gly-Val-Phe- 
Thr-Ser-Asp-Phe-Ser-Lys-Leu-Leu-Gly-Gln-Leu-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Met-NH*. The 
differences between the structures of porcine and human PHI are at position 12 (Arg/Lys replacement) and 
at position 27 (Ile/Met). 
Human PHI Porcine PHI Bovine PHI Brain peptide Gut peptide C-terminal amide 
VIPIPHIprecursor 
1. INTRODUCTION 
PHI is a heptacosapeptide originally isolated 
from porcine upper intestine [1,2] by using a 
chemical detection method [3] for its C-terminal 
amidated structure, which is a unique chemical 
feature shared with many hormonal and neural 
peptides. PHI was found to be structurally similar 
to members of the glucagon-secretin peptide 
family, especially to vasoactive intestinal peptide 
(VIP) [2]. Further, the peptide has been shown to 
exhibit a number of biological activities similar to 
VIP. For example, it stimulates insulin secretion 
[4,5] and pancreatic exocrine secretion [2,6]. PHI 
causes vasodilation [7], increases intestinal fluid 
transport [8,9] and relaxes tracheal [7,10] and 
gallbladder [l l] smooth muscle. It is also a potent 
prolactin releasing factor [ 121. Immunoreactive 
PHI is widely distributed in various nerve-con- 
taining tissues, including brain [ 13,141, intestine 
Abbreviations: PHI, peptide HI, peptide having N-ter- 
minal histidine and C-terminal isoleucine; HPLC, high- 
performance liquid chromatography 
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[15], respiratory tract [7,10] and pancreas [16]. 
Recently, a peptide was isolated from porcine 
brain and shown to be identical in primary struc- 
ture to the PHI of intestinal origin [17]. 
We report here the isolation of the human form 
of PHI from human colonic extracts. The results 
of amino acid sequence analysis establish that the 
primary structure of human PHI differs from por- 
cine PHI in two positions. 
2. MATERIALS AND METHODS 
Reagents for sequence analysis were of sequanal 
grade or were redistilled from analytical grade, and 
acetonitrile was of HPLC grade (Rathburn Chemi- 
cal, Scotland). Polyamide thin-layer plates were 
obtained from Schleicher & Schtill and thermolysin 
(EC 3.4.23.4) from Daiwa Kasei K.K., Osaka. 
Human PHI was assayed by the chemical method 
in [3]. Reversed-phase HPLC was performed in a 
Waters instrument using a pBondapak Cl8 or 
phenyl column under conditions described in the 
legends to figs.l-3. Amino acid compositions were 
determined with a Beckman 121 M amino acid 
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analyzer after hydrolysis of samples in 5.7 M 
HC1/0.5% phenol at 110°C for 24 h. Stepwise 
Edman degradation of the intact peptide was per- 
formed, using a 0.1 M Quadrol program, in a 
Beckman 890D liquid-phase sequencer in the 
presence of glycine precycled with polybrene [ 181. 
Phenylthiohydantoin amino acids were determined 
by HPLC [19] and N-terminal amino acids were 
identified by the dansyl chloride method [20]. 
3. RESULTS 
3.1. Isolation procedures 
Human PHI was purified from a starting 
material obtained as a side fraction during isola- 
tion of human VIP [21] from colonic extracts. 
Briefly, human colon (2.5 kg), obtained from 
patients undergoing surgery for carcinoma of the 
colon, was boiled in water for lOmin, frozen, 
minced and extracted at 5°C with 0.5 M acetic 
acid. Peptides in the extracts were adsorbed onto 
alginic acid, eluted with 0.2M HCI, and precipi- 
tated with NaCl at saturation. The precipitate was 
collected and dissolved in water, the pH adjusted 
to 4, and then the peptides were reprecipitated with 
NaCl. This second precipitate (5 g wet wt) was 
suspended in methanol containing 0.05% mercap- 
toethanol under constant stirring for 15 min and 
Fig. 1. Reversed-phase HPLC profile of the PHI fraction 
from the CM-cellulose chromatography. An aliquot 
(3.5 mg) was applied to a PBondapak Cl8 column 
(7.8 x 300mm) and eluted at a flow rate of 2ml/min, 
using a linear gradient of 0.12% CF&OOH/H20 and 
0.1 @i’o CFJCOOHXHJCN. The dashed line indicates the 
gradient profile. The HPLC fractions were lyophilized 
and aliquots were subjected to the chemical assay for 
PHI. The peak containing PHI is shown by the hatched 
ELUTION VOLUME (ml) 
Fig.2. Reversed-phase HPLC profile of the PHI fraction 
(fig. 1). The fraction (0.26 mg) was applied to apBonda- 
pak phenyl column (3.9 x 300 mm) and eluted at a flow 
rate of 1 ml/min with the same solvent systems as 
described in fig.1. The ‘peak (hatched area) contained 
human PHI. For comparison, the elution volume bf 
area. porcine PHI is indicated by the arrow. 
then filtered. The pH of the filtrate was adjusted 
to 7.5 (glass electrode) and the resulting precipitate 
was removed by filtration. The pH of the methanol 
extract was re-adjusted to 2.7, and the peptides in 
the extract were precipitated by addition of 4~01 
ether. The ether precipitate was collected by centri- 
fugation and dried under vacuum. The dried pre- 
cipitate (0.94) was dissolved in 0.2 M acetic acid 
and chromatographed on a Sephadex G-25 (fine) 
column with 0.2 M acetic acid. The fractions con- 
taining the major peak were combined and lyo- 
philized. An aliquot (35 mg) of the fraction (55 mg) 
was further purified by ion-exchange chromato- 
graphy on a CM-cellulose column with step-wise 
elution (0.02, 0.06, 0.1 and 0.2 M ammonium 
bicarbonate). The fraction, eluting at 0.02 M 
ammonium bicarbonate, was found to contain a 
high concentration of a peptide with C-terminal 
methionine amide. This fraction (9.9mg) was 
therefore subjected to further purification by 
reversed-phase HPLC. Fig. 1 illustrates the HPLC 
elution profile on a /cBondapak Cl8 column. This 
HPLC purification step yielded a total of 0.26 mg 
of the fraction containing PHI. This material was 
rechromatographed successively, first on apBonda- 
pak phenyl column (fig.2), which yielded 0.05 mg 
of the PHI-containing fraction, and then on a 
p Bondapak C-l 8 column (fig.3). The final product 
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Fig.3. Final HPLC purification of human PHI. The 
PHI fraction (0.05 mg, Fig.2) was re-chromatographed 
on a pBondapak Cl8 column (3.9 x 300 mm) at a flow 
rate of 1 ml/min using the same solvent systems as in 
fig.1. The major peak (hatched area) contained pure 
human PHI and this fraction was subjected to structural 
analysis. The elution volume of porcine PHI is given by 
Edman degradation in a Beckman 890D liquid- 
phase sequencer which established the amino acid 
sequence up to residue 24 and traces of residue 26. 
The repetitive yield was Al2-19: 89% and Leurs-2s: 
97%. The complete amino acid sequence of the 
human peptide is deduced from the results com- 
bined with sequence analysis, terminal determina- 
tions and amino acid analysis, as in fig.4. 
the arrow. 4. DISCUSSION 
(8 nmol) was subjected to amino acid analysis, ter- 
minal determinations and sequence analysis. 
3.2. Structural analysis 
The results of amino acid analysis suggested that 
the peptide consisted of 27 amino acid residues: 
2 Ala, 2 Asx, 2 Glx, 2 Gly, 1 His, 5 Leu, 3 Lys, 
1 Met, 2 Phe, 4 Ser, 1 Thr, 1 Tyr, 1 Val. The N-ter- 
minal residue of the peptide was found to be histi- 
dine, which is identical to that of porcine PHI. 
Treatment of the peptide with thermolysin yielded 
both methionine amide and leucylmethionine 
amide as identified by the chemical method in [3]. 
Thus, the C-terminal structure of the human pep- 
tide should be -Leu-Met-NHz, which is different 
from that of the porcine peptide, -Leu-Ile-NHz. 
The intact peptide (5 nmol) was subjected to 
15 10 17 18 19 a0 21 12 23 2, 25 26 21 
Gly-GIn-L~u-Sar-Ala-Lyr-Ly~-Tyr-L.u.Glu-S~r-Leu-Me1-NH2 
Fig.4. The complete amino acid sequence of human 
PHI. 




Fig.5. Comparison of the primary structures of por- 
cine, human and bovine PHI. Positions with residue 
replacements in relation to porcine PHI are underlined. 
It has been demonstrated that high concentra- 
tions of immunoreactive PHI occur in human in- 
testine, especially in colon [16]. We have therefore 
chosen the human colon as a starting material for 
the isolation of human PHI. The results of the 
chemical assay revealed that a material, obtained 
as a side fraction during the purification of human 
VIP [21], contained a high concentration of a pep- 
tide with C-terminal methionine amide. This side 
fraction was expected to contain PHI, since it was 
prepared by similar purification procedures as 
those used for the isolation of PHI from porcine 
intestine [2]. However, unlike porcine PHI, the 
human material contained no peptide with a C- 
terminal isoleucine amide, but one with C-terminal 
methionine amide. It was noted that this human 
peptide was eluted at slightly different volumes in 
HPLC from those of porcine PHI (fig.2,3). The 
structural studies show this peptide to be a human 
variant of PHI. The structural differences between 
the porcine and human peptides are found at two 
of the 27 residue positions, an Arg/Lys replace- 
ment at position 12 and an Ile/Met replacement at 
position 27. These replacements can be explained 
genetically by single nucleotide exchanges. The 
small structural differences suggest that the two 
peptides probably have similar biological proper- 
ties. 
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Authors in [22] recently reported the primary 
structure of a human VIP precursor, deduced from 
the cDNA sequence of human neuroblastoma 
cells, contained the sequences of both VIP and a 
PHI-like peptide, PHM-27. The primary structure 
of human PHI, isolated from human colon in this 
study, is identical to that of PHM-27, indicating 
that PHM-27 in the VIP precursor can indeed 






In addition to human PHI we recently isolated 
PHI from bovine intestine (submitted). The struc- 
tural difference between porcine and bovine PHI is 
only one position in the 27 residues: Phe/Tyr 
replacement at position 10. All presently known 
PHI structures are compared in fig.5. It remains to 
be determined whether the differences in primary 
structures of the PHI molecules result in any 
significant difference in biological and immuno- 
logical properties. 
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